Why the study?
There is limited experience with the use of the investigational drug pocapavir in young children with enteroviral infection.
Does pocapavir clear prolonged immunodeficiency-associated vaccine-derived type 3 poliovirus infection in an infant with X-linked agammaglobulinemia?
Does pocapavir clear prolonged immunodeficiency-associated vaccine-derived type 3 poliovirus infection in an infant with X-linked agammaglobulinemia?
Pocapavir may be an effective treatment for clearing prolonged immunodeficiency-associated vaccine-derived poliovirus infection in immunocompromised infants.
Pocapavir may aid iVDPV clearance in XLA; hypothesis-generating, needs controlled confirmation before practice change.
Pocapavir exhibits antiviral activity against both polio and nonpolio enteroviruses. There is limited experience of the use of this investigational drug in young children with enteroviral infection. We describe the successful clearance of prolonged immunodeficiency-associated vaccine-derived type 3 poliovirus infection by pocapavir in an infant with underlying X-linked agammaglobulinemia.
No takes yet. Share an insight, caveat, or question.
Copelyn et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: